3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Recurrence
1
Lymphoma, T-Cell, Peripheral
1
Hodgkin Disease
1
Interventions
Dexamethasone
29
Cyclophosphamide
21
Rituximab
17
Cytarabine
16
Bortezomib
13
Gemcitabine
12
fludarabine
11
Methotrexate
11
Lenalidomide
10
Filgrastim
10
Vincristine
9
Etoposide
9
pomalidomide
8
pembrolizumab
8
Paclitaxel
8
Azacitidine
8
venetoclax
7
carfilzomib
7
Doxorubicin
7
Docetaxel
7
Cyclosporine
7
Calcium Dobesilate
7
Antilymphocyte Serum
7
fludarabine phosphate
6
Topotecan
6
Temozolomide
6
Radiotherapy
6
Peripheral Blood Stem Cell Transplantation
6
Mitoxantrone
6
daratumumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Recurrence
×
AFM13
×
Clear all
NCT05883449
2025-08-20
LuminICE-203
Affimed GmbH
Phase 2
Terminated
25 enrolled
21 charts